Amylyx Pharmaceuticals, Inc./$AMLX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
Ticker
$AMLX
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
123
ISIN
US03237H1014
Website
AMLX Metrics
BasicAdvanced
$579M
-
-$3.02
-0.59
-
Price and volume
Market cap
$579M
Beta
-0.59
52-week high
$6.70
52-week low
$2.60
Average daily volume
1.1M
Financial strength
Current ratio
12.054
Quick ratio
11.397
Long term debt to equity
0.162
Total debt to equity
0.686
Profitability
EBITDA (TTM)
-206.808
Gross margin (TTM)
7,790.41%
Net profit margin (TTM)
17,205.74%
Operating margin (TTM)
16,317.06%
Effective tax rate (TTM)
0.29%
Revenue per employee (TTM)
-$10,000
Management effectiveness
Return on assets (TTM)
-40.72%
Return on equity (TTM)
-83.24%
Valuation
Price to revenue (TTM)
-371.026
Price to book
2.87
Price to tangible book (TTM)
2.87
Price to free cash flow (TTM)
-1.94
Free cash flow yield (TTM)
-51.55%
Free cash flow per share (TTM)
-335.09%
Growth
Revenue change (TTM)
-100.32%
Earnings per share change (TTM)
185.96%
3-year revenue growth (CAGR)
64.64%
3-year earnings per share growth (CAGR)
-23.63%
Bulls say / Bears say
Analysts have upgraded Amylyx Pharmaceuticals' stock, with Bank of America raising its rating from 'neutral' to 'buy' and increasing the price target from $4.20 to $10.00, indicating confidence in the company's future prospects. (Defense World)
Institutional investors are showing interest in Amylyx Pharmaceuticals, with ExodusPoint Capital Management LP acquiring new holdings in the company, suggesting potential growth and stability. (MarketBeat)
Despite recent challenges, Amylyx Pharmaceuticals' management is actively addressing issues, including working with the FDA to voluntarily discontinue marketing for Relyvrio, which may lead to a more focused and effective product pipeline. (Bloomberg)
Amylyx Pharmaceuticals announced that its Phase 3 PHOENIX Trial for RELYVRIO did not meet its primary endpoint, leading to an 85% drop in share price during intraday trading on March 8, 2024. (KGET)
The company is facing a securities fraud class action lawsuit alleging that it overstated RELYVRIO's commercial prospects and failed to disclose declining prescription rates and patient discontinuations. (GlobeNewswire)
Insider selling activity has been observed, with CEO Joshua B. Cohen selling 11,851 shares on February 3, 2025, which may indicate a lack of confidence in the company's short-term prospects. (InsiderTrades.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.
AMLX News
AllArticlesVideos
Amylyx Eyes $2B Opportunity In Post-Surgery Sugar Crash Market
Benzinga·3 days ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation
Accesswire·2 weeks ago
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Amylyx Pharmaceuticals, Inc. stock?
Amylyx Pharmaceuticals, Inc. (AMLX) has a market cap of $579M as of June 28, 2025.
What is the P/E ratio for Amylyx Pharmaceuticals, Inc. stock?
The price to earnings (P/E) ratio for Amylyx Pharmaceuticals, Inc. (AMLX) stock is 0 as of June 28, 2025.
Does Amylyx Pharmaceuticals, Inc. stock pay dividends?
No, Amylyx Pharmaceuticals, Inc. (AMLX) stock does not pay dividends to its shareholders as of June 28, 2025.
When is the next Amylyx Pharmaceuticals, Inc. dividend payment date?
Amylyx Pharmaceuticals, Inc. (AMLX) stock does not pay dividends to its shareholders.
What is the beta indicator for Amylyx Pharmaceuticals, Inc.?
Amylyx Pharmaceuticals, Inc. (AMLX) has a beta rating of -0.59. This means that it has an inverse relation to market volatility.